Compare DH & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DH | ANIX |
|---|---|---|
| Founded | 2011 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.6M | 102.6M |
| IPO Year | 2021 | 2013 |
| Metric | DH | ANIX |
|---|---|---|
| Price | $0.96 | $2.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $3.08 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 243.0K | 113.0K |
| Earning Date | 05-07-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.28 | 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $241,521,000.00 | $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.89 | $2.44 |
| 52 Week High | $4.70 | $5.46 |
| Indicator | DH | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 42.22 | 51.78 |
| Support Level | $0.93 | $2.74 |
| Resistance Level | $1.19 | $3.11 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 25.01 | 36.88 |
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.